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P-Reactive Protein and Electrocardiographic
T-Segment Depression Additively Predict Mortality
he Strong Heart Study
eter M. Okin, MD, FACC,* Mary J. Roman, MD, FACC,* Lyle G. Best, MD,† Elisa T. Lee, PHD,‡
ames M. Galloway, MD, FACC,§ Barbara V. Howard, PHD, Richard B. Devereux, MD, FACC*
ew York, New York; Timber Lake, South Dakota; Oklahoma City, Oklahoma; and Washington, DC
OBJECTIVES This study was designed to examine whether high-sensitivity C-reactive protein (CRP) and
electrocardiographic (ECG) ST-segment depression (STD) have additive utility for predict-
ing cardiovascular disease (CVD) death and all-cause death (ACD).
BACKGROUND C-reactive protein, a marker of systemic inflammation, and ECG STD, an index of
myocardial ischemia and hypertrophy, independently predict mortality.
METHODS Electrocardiograms and CRP levels were examined in 2,155 American Indian participants in
the second Strong Heart Study examination. ST-segment depression50 V (n 127) and
CRP 7.0 mg/l (defining the upper quartile of CRP levels, n  540) were considered
abnormal.
RESULTS After 5.2  1.2 years follow-up there were 95 CVD deaths and 310 ACD. In univariate Cox
analyses, the combination of CRP and ECG STD improved risk stratification compared to
either alone, with the presence of both CRP 7.0 and ECG STD associated with a 7.7-fold
increased risk of CVD death (95% confidence interval [CI] 3.3 to 18.2) and a 6.5-fold
increased risk of ACD (95% CI 4.1 to 10.3). After adjustment for age, gender, and relevant
risk factors, the combination of high CRP and STD remained predictive of CVD death and
ACD, with the presence of both abnormal CRP and STD associated with the highest risks
of CVD death (hazard ratio [HR] 3.2, 95% CI 1.1 to 10.5) and ACD (HR 3.9, 95% CI 2.1
to 7.2) and the presence of either high CRP or abnormal STD associated with intermediate
risks of CVD death (HR 2.2, 95% CI 1.4 to 3.4) and ACD (HR 1.5, 95% CI 1.2 to 2.0).
CONCLUSIONS The combination of ECG STD and CRP increases the risk of mortality, demonstrating the
additive impacts of active inflammation and preclinical CVD on prognosis. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.072Cardiol 2005;45:1787–93) © 2005 by the American College of Cardiology Foundation
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ohe resting electrocardiogram (ECG) is an inexpensive and
idely used noninvasive tool for assessing risk in
opulation-based studies and clinical practice. ST-segment
epression (STD) on the ECG, a sign of ventricular re-
olarization abnormality, is a well-established marker of risk
n the general population (1–10) that is also strongly
ssociated with underlying cardiovascular disease (CVD),
ncluding left ventricular hypertrophy (11,12). Indeed, even
inimal degrees of computer-measured STD are associated
ith higher left ventricular mass and greater prevalence of
natomic ventricular hypertrophy (11) and provide addi-
ional prognostic information beyond that afforded by echo-
ardiographic hypertrophy and traditional risk factors (10).
C-reactive protein (CRP), a marker of systemic inflam-
ation, has been demonstrated to predict incident CVD,
ypertension, systemic atherosclerosis, sudden death, and
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005, accepted February 22, 2005.VD and all-cause mortality (13–26). The additive prog-
ostic value of combining CRP with other markers of risk,
uch as low-density lipoprotein (LDL) or total cholesterol
19), glycated hemoglobin (20), metabolic syndrome
21,22), systemic hypertension (23), and Framingham risk
cores (24,25) to improve risk stratification has been well
ocumented. However, there are few data regarding the
elationship between STD and CRP (27,28), and whether
hese two readily available noninvasive risk factors provide
dditive prognostic value has not been examined. Thus, the
resent study examined the relationship between high-
ensitivity CRP and ECG STD and whether CRP and
TD have additive utility for predicting CVD and all-cause
ortality, controlling for clinical and demographic variables
hat could confound these relationships.
ETHODS
tudy population. The Strong Heart Study is a
opulation-based study of CVD and its risk factors in
merican Indians from 13 communities in Arizona, Okla-
oma, and North and South Dakota. Information about the
opulation, methods, and enrollment procedures for the
tudy has previously been reported in detail (8,9,11,29,30).
he current study examined a subset of 2,155 of the 3,638
riginal participants in the second Strong Heart Study exam
64% women, mean age 59 8 years) who had digital ECG
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C-Reactive Protein and ST-Segment Depression June 7, 2005:1787–93ecords showing sinus rhythm with no bundle branch block
nd with CRP levels.
lectrocardiography. Standard 12-lead ECGs were per-
ormed with MAC-PC or MAC-12 digital ECG systems
GE Medical Systems, Milwaukee, Wisconsin) as previ-
usly described (8,9,11). Absolute ST-segment deviation
as measured by computer with 5-V precision at the
idpoint of the ST-segment. ST-segment depression 50
V in any lead (excluding aVR) was considered abnormal, a
alue that corresponded to the 95th percentile of ECG
TD and that stratified mortality risk in participants in the
rst Strong Heart Study examination (8).
RP determination. C-reactive protein was measured us-
ng an in-house developed enzyme-linked immunosorbent
ssay using purified CRP and anti-CRP antibodies from
alBioChem (La Jolla, California) (31). This assay has been
sed extensively in epidemiologic studies and in the valida-
ion of the commercially available assay for high-sensitivity
RP (32). The coefficient of variation is approximately 8%.
-reactive protein was considered abnormal if 7.0 mg/l,
efining the upper quartile of CRP levels in the study
opulation.
etermination of end points. Deaths were identified and
erified and were classified as due to CVD if caused by
yocardial infarction, stroke, sudden death from coronary
able 1. Clinical Characteristics According to Level of C-Reactiv
Variable
CRP <7.0 mg/l
(n  1,615)
CRP >7.0 mg/
(n  540)
ge (yrs) 60  8 59  7
ender (% female) 60.3 74.8
ody mass index (kg/m2) 30.3  5.7 32.8  6.7
ystolic BP (mm Hg) 129  20 129  20
iastolic BP (mm Hg) 75  10 75  10
DL cholesterol (mg/dl) 42  14 41  12
DL cholesterol (mg/dl) 121  34 114  35
riglycerides (mg/dl) 157  108 158  136
lbuminuria (log mg/g) 3.17  1.99 3.62  2.09
asting glucose (mg/dl) 152  79 164  83
revalent CHD (%) 5.0 7.6
moking (% current) 30.7 28.5
iabetes (%) 45.2 56.0
ibrinogen (mg/dl) 348  72 415  91
-reactive protein (mg/l) 3.11  1.75 17.34  14.54
TD (V) 17  22 17  21
Abbreviations and Acronyms
ACD all-cause death
CI  confidence interval
CRP  C-reactive protein
CVD cardiovascular disease
ECG electrocardiogram/electrocardiographic
HDL high-density lipoprotein
HR  hazard ratio
LDL  low-density lipoprotein
STD  ST-segment depressionP  blood pressure; CHD  coronary heart disease; CRP  C-reactive protein; HDL
epression.eart disease, or congestive heart failure as determined by
tandardized review by the mortality committee (8,29).
ata and statistical analyses. Data were analyzed with
PSS, release 12.0 (SPSS Inc., Chicago, Illinois). Data are
resented as mean  SD for continuous variables and as
roportions for categorical variables. Mean values were
ompared between groups using two-way analysis of vari-
nce to adjust for possible gender differences. Proportions
ere compared by chi-square tests. Mortality rates were
alculated and plotted by the Kaplan-Meier product-limit
ethod; death rates were compared between groups with
he log-rank test. Mortality analyses were performed by
tting Cox proportional hazards models to the data with
tratification by center. The estimated hazard ratio of death
ssociated with positive test outcomes was computed as the
ntilog of the estimated coefficient for dichotomous vari-
bles. The 95% CI of each relative risk was calculated from
he estimated coefficients and their standard errors, and
ald chi-square statistics and probability values were cal-
ulated. To test the independence of STD and CRP as
redictors of mortality, both variables were entered together
nto multivariate Cox models with a forward selection
rocedure. The models also included covariates that were
ignificant predictors of CVD or all-cause mortality found
n the univariate Cox models. To test the complementary
nformation provided by CRP and STD criteria, a com-
ined test criterion was derived that incorporated both
easures into three categories: both STD and CRP nega-
ive, either STD or CRP positive, and both STD and CRP
ositive. For all tests, a two-tailed p value 0.05 was
onsidered significant.
ESULTS
atient characteristics. After a mean follow-up of 5.2 
.2 years there were 310 deaths from all causes, including 95
VD deaths. Clinical characteristics of participants grouped
otein and Degree of ST-Segment Depression at Baseline
p Value
STD <50 V
(n  2,028)
STD >50 V
(n  127) p Value
0.005 59  8 61  8 0.094
0.001 64.0 63.0 0.849
0.001 30.9  6.1 31.4  5.9 0.407
0.907 129  20 134  25 0.033
0.459 75  10 75  11 0.918
0.304 42  13 40  15 0.092
0.001 119  34 121  39 0.724
0.816 155  110 188  175 0.040
0.001 3.23  1.98 4.20  2.42 0.001
0.004 154  79 173  96 0.029
0.024 5.0 15.0 0.001
0.379 30.5 25.2 0.001
0.001 47.0 62.2 0.001
0.001 363  79 391  115 0.007
0.001 6.48  8.83 9.77  18.09 0.044
0.890 13  15 75  29 0.001e Pr
l high-density lipoprotein; LDL  low-density lipoprotein; STD  ST-segment
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June 7, 2005:1787–93 C-Reactive Protein and ST-Segment Depressionccording to the level of CRP and degree of STD are
xamined in Table 1. Compared to those with lower CRP
evels, the 540 participants with CRP 7.0 mg/l were
lightly younger, more likely to be women, had higher body
ass indexes, lower LDL cholesterol, higher fasting glucose
nd fibrinogen levels, greater albuminuria, higher preva-
ences of coronary heart disease and diabetes, and were
lightly less likely to be current smokers, but did not differ
ith respect to systolic or diastolic pressure, high-density
ipoprotein (HDL) cholesterol or triglyceride levels, or
egree of STD. The 127 participants with STD 50 V
ad higher systolic pressures, higher triglyceride, fasting
lucose, fibrinogen, and CRP levels; had greater albumin-
ria and prevalences of coronary heart disease and diabetes;
nd were less likely to be current smokers, but did not differ
ith respect to age, gender, body mass index, diastolic
ressure, and HDL or LDL cholesterol levels compared to
articipants with less STD. C-reactive protein and STD
ere only minimally correlated with each other (r  0.06,
 0.006).
rediction of cardiovascular and all-cause mortality. In
ox analyses stratified for study center, abnormal STD and
RP were each significant predictors of CVD and all-cause
ortality (Table 2, Figs. 1 and 2). ST-segment depression
50 V was associated with a 4-fold increased risk of
VD death and with a 2.5-fold increased risk of all-cause
ortality, with CVD mortality of 15.0% (19 of 127) and
ll-cause mortality of 32.3% (41 of 127), compared with
.7% (76 of 2,028) and 13.3% (269 of 2,028), respectively,
n those with STD 50 V. C-reactive protein 7.0 mg/l
as associated with a two-fold increased risk of CVD death
nd with a nearly two-fold higher risk of death from any
ause, with CVD mortality of 6.7% (35 of 540) and total
ortality of 20.0% (128 of 540), compared with 3.7% (59 of
,615) and 12.5% (202 of 1,615), respectively, in those with
ower CRP levels.
After adjustment for the possible predictive values of age,
ender, body mass index, diastolic and systolic blood pres-
ures, HDL and LDL cholesterol, triglyceride, fasting
lucose and fibrinogen levels, albuminuria, alcohol use,
iabetes, and history of smoking or prevalent coronary heart
isease, both STD 50 V and an elevated CRP remained
able 2. Cox Proportional Hazards Models of High-Sensitivity C
rediction of All-Cause and Cardiovascular Mortality
Variable
All-Cause Mortality†
Hazard Ratio 95% CI Chi-Square
nivariate
STD 50 V 2.63 1.90–3.66 33.2
CRP 7.0 mg/l 1.80 1.42–2.27 23.9
ultivariate*
STD 50 V 1.61 1.08–2.40 5.4
CRP 7.0 mg/l 1.69 1.30–2.20 15.0
Including both ST-segment depression 50 V and hsCRP 7.0 mg/l in the m
lbuminuria also remain in the multivariate Cox model. ‡Age, gender, and albuminu
CI  confidence interval; other abbreviations as in Table 1.ignificant predictors of CVD and all-cause mortality (Ta-
a
dle 2). Predictive values of STD and CRP for CVD and
ll-cause mortality were not dependent on the partition
alues selected for test positivity: considering STD and
RP as continuous variables preserved their independent
redictive value for both CVD (HR 1.25, 95% CI 1.03 to
.52 per 25 V of STD and HR  1.015, 95% CI 1.000
active Protein and ST-Segment Depression Criteria for
Cardiovascular Mortality‡
Value Hazard Ratio 95% CI Chi-Square p Value
0.001 4.37 2.64–7.23 32.8 0.001
0.001 2.06 1.36–3.12 11.5 0.001
0.020 1.92 1.03–3.61 4.2 0.042
0.001 2.06 1.30–3.28 9.4 0.002
Age, body mass index, LDL cholesterol, fasting glucose, history of smoking, and
o remained in the multivariate Cox model.
igure 1. Kaplan-Meier plots of cumulative cardiovascular mortality (A)-Re
p



odel. †nd all-cause mortality (B) according to the magnitude of ST-segment
epression (STD) partitioned at 50 V.
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C-Reactive Protein and ST-Segment Depression June 7, 2005:1787–93o 1.039 per 1 mg/l of CRP) and all-cause mortality (HR
.13, 95% CI 1.03 to 1.25 and HR  1.014, 95% CI 1.005
o 1.023) in multivariate analyses.
igure 2. Kaplan-Meier plots of cumulative cardiovascular mortality (A)
nd all-cause mortality (B) according to high-sensitivity C-reactive protein
CRP) partitioned at 7.0 mg/l.
able 3. Cox Proportional Hazards Models of Combined High-S
or Prediction of All-Cause and Cardiovascular Mortality
Variables
All-Cause Mo
Hazard
Ratio 95% CI Ch
nivariate
Combined CRPSTD
CRP/STD (n  1,524) 1 —
CRP/STD or CRP/STD
(n  595)
1.69 1.33–2.15
CRP/STD (n  36) 6.48 4.08–10.31
ultivariate*
Combined CRPSTD
CRP/STD (n  1,524) 1 —
CRP/STD or CRP/STD
(n  595)
1.51 1.16–1.96
CRP/STD (n  36) 3.89 2.11–7.16Same variables remain in the multivariate models as listed in Table 2.
Abbreviations as in Table 2.ombined high-sensitivity CRP and ECG STD criteria.
ecause CRP and STD criteria provided independent
rognostic information, the ability of the combination of
hese variables to improve prediction of mortality was
ssessed (Table 3, Fig. 3). In Cox analyses stratified by study
enter, the combined CRP and ECG STD variable im-
roved risk stratification compared to either CRP or STD
lone for both CVD and all-cause mortality, with the
resence of both ECG STD and an elevated CRP associ-
ted with the greatest risks. Cardiovascular disease mortality
as 16.7% (6 of 36) in participants with both STD50 V
nd CRP 7.0 mg/l, 7.2% (43 of 595) in those with either
CG STD or an abnormal CRP, and only 3.0% (46 of
,524) in those in whom both variables were negative (p 
.0001). All-cause mortality was 55.6% (20 of 36) in the
resence of both ECG STD and an elevated CRP, 18.3%
109 of 595) when either variable was abnormal, and 11.9%
181 of 1,524) when both tests were negative (p  0.0001).
ultivariate Cox analyses (Table 3) demonstrated that after
djustment for other potential predictors of mortality, the
ombination of ECG STD and an elevated CRP level
emained a significant predictor of CVD and all-cause
ortality, with the presence of both ECG STD and
ncreased CRP associated with a 3.2-fold increased risk of
VD death and a 3.9-fold increased risk of all-cause
ortality after adjusting for covariates. Predictive value of
he combined criterion was not dependent on use of the
pper quartile of CRP to define abnormality: the combined
redictive value of CRP and STD remained significant if
RP was partitioned using the population median (3.8
g/l) or 90th percentile (15.0 mg/l) values.
ISCUSSION
his study demonstrates that the combination of STD on
he ECG and elevated high-sensitivity CRP is associated
ith an increased risk of CVD and all-cause mortality.
lectrocardiographic STD and increased CRP provide ad-
tivity C-Reactive Protein and ST-Segment Depression Criteria
Cardiovascular Mortality
are p Value
Hazard
Ratio 95% CI Chi-Square p Value
— 1 — — —
0.001 2.66 1.75–4.04 20.9 0.001
0.001 7.72 3.28–18.16 21.9 0.001
— 1 — — —
0.002 2.17 1.37–3.44 10.9 0.001
0.001 3.15 1.05–10.52 4.2 0.048ensi
rtality
i-Squ
—
18.7
62.3
—
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June 7, 2005:1787–93 C-Reactive Protein and ST-Segment Depressionitive prognostic information, independent of each other
nd of other risk factors known to predict mortality. The
dditive prognostic value of increased CRP and STD
ersists across the full range of CRP and STD values and is
ndependent of factors previously demonstrated to provide
dditional prognostic information in the presence of an
levated CRP (19–26). The absence of both an elevated
RP and ECG STD identifies a large group at relatively
ow five-year risk of death, whereas the presence of both
bnormalities identifies a subgroup with a markedly in-
reased five-year mortality. These findings support the
bility of combining simple computerized ECG STD and
RP criteria to improve risk stratification.
elationship of CRP and STD to outcome. The separate
redictive values of CRP and ECG STD have been well
ocumented in a range of populations, with convincing
vidence for continuous relationships between increasing
alues of both STD and CRP and event rates (8,9,11,13–
6). Quantitative measures of STD using computerized
CG have been associated with an increased risk of ana-
igure 3. Kaplan-Meier plots of cumulative cardiovascular mortality (A)
nd all-cause mortality (B) according to combined ST-segment depression
STD) and high-sensitivity C-reactive protein (CRP) criteria. (STD/
RP represents both negative; STD or CRP represents either
ositive; STD/CRP represents both positive).omic hypertrophy (11) and with both CVD and all-cause eortality (8,9), with the combination of ECG STD and
chocardiographic left ventricular hypertrophy providing
omplementary prognostic information for these outcomes
9). Similarly, the prognostic value of CRP has been
xtensively documented in a variety of prospective epidemi-
logic studies, with evolving evidence that CRP provides
dditive prognostic information beyond that afforded by
ssessment of cholesterol levels (19) and the Framingham
isk score (24,25), further supporting the additive value of
RP as a risk factor for vascular disease and outcomes.
owever, only limited data exist on the relationship be-
ween CRP and ECG findings (27,28), and the value of
ombining CRP and ECG STD for risk prediction has
reviously not been examined.
In a population-based study of 8,076 subjects, Asselbergs
t al. (27) demonstrated that although ST-segment and
-wave abnormalities by Minnesota code were modest
nivariate correlates of an increased CRP, only Q-wave
yocardial infarction by Minnesota code remained associ-
ted with increased CRP levels after adjusting for standard
ardiovascular risk factors. The current study demonstrates
nly a weak correlation between CRP and ECG STD as
ontinuous variables and that each provides significant
ndependent prognostic information for both CVD and
CD (Table 2), providing the impetus for combining the
ariables to enhance risk stratification. Importantly, the
resent study further demonstrates that the additive predic-
ive value of STD and CRP is independent of the prognos-
ic value of cholesterol and other risk factors that constitute
he Framingham risk score, and of serum fibrinogen levels
nd albuminuria, risk factors previously demonstrated to
redict outcome in this population (9,30). In light of the
ecent report demonstrating the additive value of ECG
TD and echocardiographic hypertrophy for predicting
ortality in this population (9), it is important to note that
nclusion of echocardiographic hypertrophy in alternative
ultivariate Cox models (data not shown) did not affect the
redictive value of the combined ECG STD and CRP
ariable.
These findings suggest that active inflammation (reflected
y increased CRP) and preclinical CVD (as denoted by even
inor degrees of STD on the ECG) provide complemen-
ary and additive stimuli in the development of mortality
ue to atherosclerosis. Accumulating evidence suggests that
RP may play a direct role in atherogenesis at the level of
he endothelial cell and vascular smooth muscle (33–36),
hereas STD on the ECG has been directly linked with
VD, including left ventricular hypertrophy (1–12). The
nteraction of inflammation with ventricular and vascular
ypertrophy to produce atherosclerosis provides an attrac-
ive hypothesis for the additive impact of these two risk
arkers in predicting outcome.
Several aspects of the study population need to be
onsidered with respect to these findings. First, it is unclear
o what degree these findings in American Indians can be
xtrapolated to other ethnic populations. However, the
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C-Reactive Protein and ST-Segment Depression June 7, 2005:1787–93emonstrated predictive value of CRP and minor degrees of
TD in other populations when examined separately from
ach other (1–7,13–26) suggests that the combination of
RP and ECG STD will stratify risk in other populations
s well. Second, the current population has a high preva-
ence of diabetes and metabolic syndrome and is predomi-
antly women, with the attendant issues of gender differ-
nces in CRP levels and possible effects of estrogen on CRP.
owever, CRP performed similarly in men and women and
here were no significant interactions between gender and
RP in Cox analyses of the entire population. Additionally,
strogen use was limited in the population (n  137, 6.4%),
nd neither including estrogen use as an additional variable
or excluding women using estrogen altered the results.
A number of other potential limitations should also be
aken into account. First, the absence of serial CRP and
CG STD determinations precludes analysis of the impact
f changes in CRP and/or STD on risk. Second, the values
f CRP in this population of American Indians are signif-
cantly higher than those found in most prior population-
ased studies of the prognostic value of CRP (13–26).
owever, the predictive value of both STD and CRP in the
urrent population persisted when CRP was examined using
oth lower (3.8 mg/l) and higher (15.0 mg/l) partition
alues and when CRP was considered as a continuous
ariable. Previous analyses have also documented the pre-
ictive value of very high (10 mg/l) levels of CRP (25). In
ddition, exclusion of participants with CRP levels in the
ighest decile (15 mg/l) did not substantively alter the
esults of the current analyses. Lastly, it should be noted that
se of computer-measured STD 50 V for prediction of
isk has been validated in American Indian participants only
n the Strong Heart Study (8,9,11). However, utility of this
hreshold of STD, using both manual and computerized
T-segment measurements, has been extensively examined
nd confirmed in other populations using Minnesota codes
-2 and 4-3 (37,38), which are defined by the presence of
TD 50 V and 100 V.
The major implication of this study is that both high-
ensitivity CRP and ECG STD aid in routine clinical
dentification of patients at high risk. The recent interest in
evelopment of novel biomarkers that provide additional
nformation beyond that available from standard risk factors
nd are inexpensive and readily available to practitioners
39) provides further impetus for the use of CRP levels and
etermination of the magnitude of STD from the widely
vailable and inexpensive digital ECG. Although data are
merging that demonstrate clear associations between im-
roved clinical outcomes and treatment-related reductions
n CRP (40,41) and ECG markers of risk (42), whether
herapies targeted specifically at reducing these biomarkers
ill improve prognosis requires further evaluation and will
rove crucial in further delineating the role of these biomar-
ers in the serial assessment of risk.
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